References
Tsiachris D, Doundoulakis I, Pagkalidou E, et al. Pharmacologic cardioversion in patients with paroxysmal atrial fibrillation: a network meta-analysis. Cardiovasc Drugs Ther. 2021;35:293–308.
Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117:1518–25.
Vardas PE, Kochiadakis GE. Amiodarone for the restoration of sinus rhythm in patients with atrial fibrillation. Card Electrophysiol Rev. 2003;7:297–9.
Puhan MA, Schunemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630.
deSouza IS, Tadrous M, Sexton T, Benabbas R, Carmelli G, Sinert R. Pharmacologic cardioversion of recent-onset atrial fibrillation and flutter in the emergency department: a systematic review and network meta-analysis. Ann Emerg Med. 2020;76:14–30.
Nikolakopoulou A, Higgins JPT, Papakonstantinou T, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17:e1003082.
Pohjantahti-Maaroos H, Hyppola H, Lekkala M, Sinisalo E, Heikkola A, Hartikainen J. Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation. Eur Heart J Acute Cardiovasc Care. 2019;8:114–20.
Vogiatzis I, Papavasiliou E, Dapcevitch I, Pittas S, Koulouris E. Vernakalant versus ibutilide for immediate conversion of recent-onset atrial fibrillation. Hippokratia. 2017;21:67–73.
Kafkas NV, Patsilinakos SP, Mertzanos GA, et al. Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. Int J Cardiol. 2007;118:321–5.
Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
Brignardello-Petersen R, Florez ID, Izcovich A, et al. GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. BMJ. 2020;371:m3900.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing Interests
I. d. has received consulting honoraria from InCarda Therapeutics, Inc. R. A. and P. S. declare that they have no financial interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
deSouza, I.S., Allen, R. & Shrestha, P. Reassessment of Confidence in a Network Meta-analysis of Antidysrhythmic Drugs for Atrial Fibrillation Cardioversion. Cardiovasc Drugs Ther 36, 1249–1251 (2022). https://doi.org/10.1007/s10557-022-07318-y
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-022-07318-y